Imatinib Glenmark

Imatinib, the active ingredient in Imatinib Glenmark, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia, gastrointestinal stromal tumor and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients. GNH USA supplies Imatinib Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Glenmark targets malignant cells driven by specific tyrosine‑kinase pathways and is employed in the following indications: - Chronic myeloid leukemia (CML): achieves durable hematologic and cytogenetic remission. - Gastrointestinal stromal tumor (GIST): reduces tumor size and delays disease progression. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves remission rates when combined with chemotherapy.

Adverse reactions may occur with Imatinib Glenmark therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often of the ankles. - Muscle cramps: intermittent skeletal muscle discomfort. - Fatigue: generalized tiredness. - Diarrhea: loose stools, usually self‑limiting. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe neutropenia: marked reduction in white blood cells. - Cardiac failure: reduced left‑ventricular ejection fraction. - Pulmonary hypertension: increased pressure in lung arteries. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Tumor lysis syndrome: metabolic disturbances from rapid tumor breakdown.

Before initiating Imatinib Glenmark, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect neutropenia or anemia. - Assess liver function: check transaminases and bilirubin periodically. - Evaluate cardiac status: baseline and periodic echocardiograms for patients at risk. - Avoid use in pregnancy unless essential: drug is Category D and may cause fetal harm. - Use caution in renal impairment: dose adjustment may be required. - Store at room temperature: keep in the original container, protect from moisture and light.

Imatinib Glenmark can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma levels. - Potent CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce therapeutic exposure. - Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam, cyclosporine): may require dose adjustments. - QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of cardiac arrhythmias. - Warfarin: may enhance anticoagulant effect, necessitating INR monitoring.